6th May 2008 12:40
IS Pharma PLC06 May 2008 6 May 2008 IS Pharma plc ('IS Pharma' or the 'Group') Notification of Interest The Group was notified on 2 May 2008 in a letter dated 30 April 2008 thatBarclays PLC, through Barclays Stockbrokers Ltd and Gerrard InvestmentManagement Ltd, has a notifiable interest of 1,539,321 ordinary shares of 70pence each in IS Pharma. This is equivalent to 5.01% of the issued share capitalof the Group. The issued share capital of the Group is 30,754,404 ordinary shares of 70 penceper share. - ENDS - Enquiries: Financial Dynamics Limited Tel: +44(0) 20 7831 3113Billy Clegg / Edward Westropp Noble & Company Limited Tel: +44(0) 20 7763 2200Matthew Hall / Sam Reynolds IS Pharma plc Tel: +44(0) 1244 625150Tim Wright - CEOwww.ispharma.plc.uk About IS Pharma plc (AIM:ISPH): The Group focuses on building a late-stage pharmaceutical and medical devicesbusiness in the specialist hospital medicine sector. Based in the UK, IS Pharmacommercialises its portfolio in the UK directly while also consolidating itspresence in the major European markets through a strong network of distributors. Currently focused in the areas of critical care, neurology and oncology, theGroup's marketed and development brands include: - Critical Care: Volplex(R), (plasma substitute); Cryogesic(R) / Dermogesic(R), (cryo-analgesic); Haemopressin(R), (treatment of oesophageal varices); and ISOplex(R), (isotonic plasma substitute); AquiHex(R) (anti bacterial) - Neurology: Mysoline(R) (primidone), a product currently used to treat epilepsy and which IS Pharma is developing for management of Essential Tremor, a distressing condition affecting an estimated 1 in 25 over 40 year olds for which primidone is one of only two recommended treatments; Acoranil(R) (antidepressant syrup) - Oncology: Cryogesic(R), 5 FU, (an oral chemotherapeutic agent for the treatment of cancer); and most recently, Aloxi(R) (treatment of chemotherapy induced nausea and vomiting). Following the acquisition of Speciality European Pharma International AG, inApril 2008, IS Pharma adopted a new name (IS Pharma plc) and acquired aportfolio of specialist hospital pharmaceutical products and importantly theinternational rights for the critical care drug, Haemopressin (IS Pharmapreviously held rights for Haemopressin in the UK and Ireland). Products which are outside of the Group's core hospital focus or which are inearly stage of research are out-licensed, including the successful OptiFlo(TM)Catheter Maintenance Solutions (to Bard Limited) and micelle nanotechnology,which is incorporated into an early stage lidocaine based product for thetreatment of interstitial cystitis (to Plethora Solutions Limited). To find outmore please go to www.ispharma.plc.uk. OptiFlo(TM) is a trademark of C.R. Bard Inc or an affiliate This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Barclays